^
Association details:
| Biomarker: | CD20 underexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Downregulation of Chemokine CCL20 Involved in Myeloma Cells Resistant to Elotuzumab and Lenalidomide
Published date:
04/21/2021
Excerpt:
We collected 27 samples from patients with newly diagnosed MM (NDMM), and 5 samples from relapsed refractory MM (RRMM) patients with exposure to lenalidomide. The results showed that compared with NDMM, the expression of CCL20 mRNA in RRMM was lower (p < 0.01...CCL20 could therefore possibly increase the sensitivity of lenalidomide and Elotuzumab.
DOI:
https://doi.org/10.2147/OTT.S300328
